Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bacterial Phylum Chlamydiae01:29

Bacterial Phylum Chlamydiae

678
The phylum Chlamydiae or Chlamydiota is composed of a single order, Chlamydiales. This phylum consists entirely of obligate intracellular parasites that infect eukaryotic hosts. While human pathogens within this group have been studied extensively, the phylum encompasses many species capable of interacting with various eukaryotic organisms. Members of Chlamydiae are typically small cocci, approximately 0.5 μm in diameter, and exhibit a distinctive developmental cycle. As is characteristic...
678
Vaccinations01:51

Vaccinations

52.8K
Overview
52.8K
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

1.4K
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
1.4K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.3K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K
Cancer Vaccines01:30

Cancer Vaccines

1.2K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
Development of Immunocompetence01:22

Development of Immunocompetence

1.1K
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IFNγ-producing iNKTs restrict a live-attenuated chlamydia oral vaccine in the large intestine.

Frontiers in immunology·2026
Same author

Chlamydial histone homologs control developmental fitness in the next infection cycle.

mSphere·2026
Same author

The distinct trimeric structure of the immunodominant chlamydial antigen Major Outer Membrane Protein.

Nature communications·2026
Same author

Inhibition of a live-attenuated chlamydia oral vaccine in the large intestine is dependent on CD11c-expressing cells that produce IL-23.

Scientific reports·2026
Same author

Immunological evaluation of vaccines to prevent Chlamydia trachomatis infection using the human in vitro MIMIC system.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

The oral vaccine intrOv is attenuated in infecting the lower airway and inducing chronic pathology.

Infection and immunity·2026

Related Experiment Video

Updated: Mar 7, 2026

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

2.2K

Update on Chlamydia trachomatis Vaccinology.

Luis M de la Maza1, Guangming Zhong2, Robert C Brunham3

  • 1Department of Pathology and Laboratory Medicine, University of California, Irvine, Irvine, California, USA lmdelama@uci.edu.

Clinical and Vaccine Immunology : CVI
|February 24, 2017
PubMed
Summary

Developing a Chlamydia trachomatis vaccine has faced challenges due to disease exacerbation. Recent research focuses on novel formulations for effective immunization against genital infections.

Keywords:
Chlamydia muridarumChlamydia trachomatisChlamydia trachomatis vaccinesadjuvantsantigensdelivery systemsroutes of immunizationvaccinology

More Related Videos

Forward Genetic Approaches in Chlamydia trachomatis
09:03

Forward Genetic Approaches in Chlamydia trachomatis

Published on: October 23, 2013

13.3K
Markerless Gene Deletion by Floxed Cassette Allelic Exchange Mutagenesis in Chlamydia trachomatis
10:35

Markerless Gene Deletion by Floxed Cassette Allelic Exchange Mutagenesis in Chlamydia trachomatis

Published on: January 30, 2020

7.3K

Related Experiment Videos

Last Updated: Mar 7, 2026

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

2.2K
Forward Genetic Approaches in Chlamydia trachomatis
09:03

Forward Genetic Approaches in Chlamydia trachomatis

Published on: October 23, 2013

13.3K
Markerless Gene Deletion by Floxed Cassette Allelic Exchange Mutagenesis in Chlamydia trachomatis
10:35

Markerless Gene Deletion by Floxed Cassette Allelic Exchange Mutagenesis in Chlamydia trachomatis

Published on: January 30, 2020

7.3K

Area of Science:

  • Immunology
  • Vaccinology
  • Microbiology

Background:

  • Trachoma vaccine development attempts began over a century ago, yielding protective responses but also disease exacerbation in some individuals.
  • Chlamydia trachomatis is recognized as a significant sexually transmitted pathogen causing acute infections and long-term sequelae in both sexes and newborns.

Purpose of the Study:

  • To summarize recent findings on Chlamydia trachomatis vaccine development.
  • To discuss various immunization strategies, including antigens, adjuvants, routes, and delivery systems.
  • To explore the potential for a vaccine targeting Chlamydia trachomatis genital infections.

Main Methods:

  • Review of recent scientific literature on Chlamydia trachomatis vaccine research.
  • Analysis of immunization formulations and delivery systems.
  • Focus on studies utilizing the female mouse model for evaluating vaccine candidates.

Main Results:

  • Early whole-organism vaccines showed promise but led to adverse effects.
  • Current research explores diverse antigens, adjuvants, and delivery systems for improved safety and efficacy.
  • The female mouse model is a key platform for preclinical evaluation of new vaccine strategies.

Conclusions:

  • Overcoming historical challenges requires innovative vaccine approaches for Chlamydia trachomatis.
  • Optimized formulations and delivery systems are crucial for developing a safe and effective vaccine against genital Chlamydia trachomatis infections.
  • Further research is needed to translate promising preclinical findings into clinical applications.